Windtree Therapeutics Faces Delisting Notice
Ticker: WINTW · Form: 8-K · Filed: Jan 22, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: delisting, regulatory-filing, compliance, exchange-notice
TL;DR
**WINT got a delisting notice, stock liquidity at risk.**
AI Summary
Windtree Therapeutics, Inc. (WINT) filed an 8-K on January 22, 2024, to report that it has received a notice of delisting or failure to satisfy a continued listing rule or standard. This means the company is at risk of being removed from its current stock exchange, which could make its shares harder to trade and potentially reduce their value. This matters to investors because delisting often signals significant financial or operational challenges, making the stock a higher-risk investment.
Why It Matters
This filing indicates that Windtree Therapeutics is in jeopardy of being delisted from its stock exchange, which could severely impact the stock's liquidity and investor confidence.
Risk Assessment
Risk Level: high — A delisting notice indicates significant non-compliance with exchange rules, posing a high risk to the stock's tradability and value.
Analyst Insight
A smart investor would carefully evaluate the reasons for the delisting notice and the company's plan to regain compliance, as delisting can significantly impair a stock's liquidity and value. Consider reducing exposure or avoiding new positions until clarity emerges.
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 22, 2024 (date) — date of earliest event reported and filing date
- 001-39290 (null) — Commission File Number for Windtree Therapeutics, Inc.
- 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (null) — principal executive offices of Windtree Therapeutics, Inc.
- (215) 488-9300 (null) — telephone number for Windtree Therapeutics, Inc.
FAQ
What is the primary event reported in this 8-K filing by Windtree Therapeutics, Inc.?
The primary event reported is a "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing" as per Item 3.01 of Form 8-K, with the earliest event reported on January 22, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 22, 2024.
What is the business address of Windtree Therapeutics, Inc. as stated in the filing?
The business address of Windtree Therapeutics, Inc. is 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.
What is the Commission File Number for Windtree Therapeutics, Inc.?
The Commission File Number for Windtree Therapeutics, Inc. is 001-39290.
What is the significance of an 8-K filing under Item 3.01?
An 8-K filing under Item 3.01, "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing," signifies that the company has received formal notification that it is not in compliance with the listing requirements of its exchange, potentially leading to its shares being delisted.
Filing Stats: 859 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2024-01-22 16:45:14
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share   WINT   The
- $1.00 — mmon Stock") has been below the minimum $1.00 per share required for continued listin
Filing Documents
- wint20240122_8k.htm (8-K) — 24KB
- 0001437749-24-001871.txt ( ) — 153KB
- wint-20240122.xsd (EX-101.SCH) — 3KB
- wint-20240122_def.xml (EX-101.DEF) — 11KB
- wint-20240122_lab.xml (EX-101.LAB) — 15KB
- wint-20240122_pre.xml (EX-101.PRE) — 11KB
- wint20240122_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   Date: January 22, 2024 Windtree Therapeutics, Inc.             By: /s/ Craig E. Fraser     Name: Craig E. Fraser     Title: President and Chief Executive Officer